Protalix BioTherapeutics Inc (PLX)

0.30
0.00 0.81
AMEX : Health Care
Prev Close 0.30
Open 0.30
Day Low/High 0.29 / 0.31
52 Wk Low/High 0.61 / 1.78
Volume 706.63K
Avg Volume 600.50K
Exchange AMEX
Shares Outstanding 99.93M
Market Cap 29.98M
EPS 0.60
P/E Ratio 1.36
Div & Yield N.A. (N.A)

Latest News

Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older

Alfataliglicerase Approved For Pediatric Indications In Brazil For The Treatment Of Gaucher Disease In Children Four Years And Older

Approval further supports the advanced ongoing discussions with the Brazilian Ministry of Health for the supply of a significant amount of alfataliglicerase for Gaucher patients in Brazil

Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease

Protalix BioTherapeutics Doses First Patient In Global Phase III Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease

Six Sites Activated Across the United States and Europe with additional patients currently in the screening process for potential inclusion in trial

IIROC Trading Resumption - PLX

IIROC Trading Resumption - PLX

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF

Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF

Positive Pre-Clinical Data for PRX-106 Oral Anti-TNF in NASH

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Net Losses Narrowed With Clinical Progress in All Three Product Candidates

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF

Favorable Safety and Tolerability Data Demonstrates Biological Activity in the Gut and Activation of Regulatory T Cells